Liraglutide vs Semaglutide: The First Two GLP-1 Reference Standards Compared
Before the dual- and tri-agonists, two GLP-1 mono-agonists defined the class. An identity, structure, and analytical-verification comparison of Liraglutide and Semaglutide as research reference standards — CAS, formula, sequence length, fatty-acid modification, and per-lot documentation priorities.
Published June 2, 2026 · 7 min read · By Lyochem Regulatory Team
Liraglutide and Semaglutide are the two GLP-1 receptor mono-agonists that anchored the incretin class before the dual- and tri-agonists arrived. They are closely related molecules — both acylated GLP-1 analogs that bind plasma albumin to extend half-life — but they differ in fatty-acid chemistry, dosing cadence in the published literature, and the analytical behaviour a lab sees on the bench. Qualifying either as a reference standard means knowing exactly which molecule is in the vial and confirming it lot-by-lot.
What is the difference between Liraglutide and Semaglutide as research standards?
Liraglutide (CAS 204656-20-2) and Semaglutide (CAS 910463-68-2) are both selective GLP-1 receptor mono-agonist peptides built on the human GLP-1 backbone with an acylated lysine that binds albumin. They differ in the fatty-acid/linker chemistry and in molecular mass: Liraglutide is C172H265N43O51 (3751.20 g/mol) carrying a C16 (palmitoyl) diacid via a glutamic-acid spacer; Semaglutide is C187H291N45O59 (4113.58 g/mol) carrying a C18 diacid via a γGlu-2×OEG linker, with an Aib substitution at position 8 that further resists DPP-4 cleavage. Both are supplied strictly as research reference standards, verified by RP-HPLC purity plus ESI-MS identity per lot.
Identity reference
| Property | Liraglutide | Semaglutide |
|---|---|---|
| CAS | 204656-20-2 | 910463-68-2 |
| Formula | C172H265N43O51 | C187H291N45O59 |
| Average MW | 3751.20 g/mol | 4113.58 g/mol |
| Sequence length | 31 aa | 31 aa |
| Receptor target | GLP-1 (mono-agonist) | GLP-1 (mono-agonist) |
| Albumin-binding modification | C16 diacid, γGlu spacer | C18 diacid, γGlu-2×OEG linker |
| Backbone substitution | Arg34 | Aib8, Arg34 |
Each Lyochem lot confirms identity by ESI-MS against the theoretical mass for the supplied form and reproduces the value on the batch COA so it can be cited directly in a methods section. The sequence-length figure here follows the catalog convention (the human GLP-1 hormone backbone is sometimes counted as 30 residues; the analog is counted as 31 with the modified-residue numbering). Where a methods section needs a specific residue count, read it from the lot COA and the supplied structural annotation rather than a single catalog value.
Why the fatty-acid chemistry is the analytical story
Both molecules are GLP-1 analogs acylated on a lysine side chain so the conjugate binds serum albumin and circulates longer. That shared design is also the main source of their analytical and handling differences:
- The acyl chain is hydrophobic, so both peptides retain late on a C18 RP-HPLC gradient relative to an unmodified GLP-1 backbone. Semaglutide's longer C18 diacid plus OEG linker shifts its retention and ionization behaviour relative to Liraglutide's C16 spacer.
- The acylation site is a specific lysine. An incomplete or mis-positioned acylation is a closely-related impurity that an intact-mass check may not fully resolve, which is why the impurity profile and — for first-lot qualification — sequence-level evidence matter more here than for a small unmodified peptide.
- Both carry the same release-relevant handling questions: counter-ion form (acetate by default; TFA suppresses some cell-based readouts), water content by Karl Fischer (which affects true peptide mass per vial), and lyophilized stability at minus 20 degrees Celsius protected from light.
Mono-agonist context, framed for research
In the published metabolic-development literature, both Liraglutide and Semaglutide act as selective GLP-1 receptor agonists; the practical difference described in that literature is the dosing cadence the albumin-binding chemistry supports (Liraglutide's shorter spacer is associated with more frequent dosing than Semaglutide's longer linker in the clinical-development program). For a research lab, that context is useful only as background: it explains why the two are studied as a mono-agonist pair and why a metabolic study comparing incretin mechanisms might include both. It is not a property of the reagent on the bench, and Lyochem makes no therapeutic claim about either standard.
Which verification depth each one needs
For both peptides, the baseline release packet is RP-HPLC purity at 214 nm plus ESI-MS identity, water content, and counter-ion. Add LC-MS/MS sequence confirmation for first-time supplier qualification of either molecule, and for any study where the acylation-site integrity is part of the endpoint. For in vivo metabolic-model work, request bacterial endotoxin (LAL) on the specific lot, since endotoxin confounds many metabolic and inflammatory readouts.
Sourcing scale and framing
Lyochem supplies Liraglutide and Semaglutide as reference-grade research standards at milligram scale, characterized lot-by-lot, and labelled strictly Research Use Only. That is a different scope from compounding-grade or kilogram-scale API supply intended for finished-dose preparation. Some GLP-1 analogues exist as approved finished drugs under separate brand names; the material supplied here is a research reagent, and buyers are responsible for institutional biosafety review and verifying import eligibility in the destination market.
Talk to our regulatory team
Qualifying a GLP-1 mono-agonist reference standard?
Send the molecule, target purity, intended assay, and whether this is first-lot qualification. Lyochem will map the analytical packet before quote.
Frequently asked questions
- What CAS numbers and molecular weights identify Liraglutide and Semaglutide?
- Liraglutide is CAS 204656-20-2, formula C172H265N43O51, average MW 3751.20 g/mol, a GLP-1 receptor mono-agonist carrying a C16 diacid on an acylated lysine via a glutamic-acid spacer. Semaglutide is CAS 910463-68-2, formula C187H291N45O59, average MW 4113.58 g/mol, a GLP-1 receptor mono-agonist carrying a C18 diacid via a γGlu-2×OEG linker plus an Aib8 substitution. Each Lyochem lot confirms identity by ESI-MS against the theoretical mass for the supplied form.
- Are Liraglutide and Semaglutide the same kind of molecule?
- Both are selective GLP-1 receptor mono-agonist peptides built on the human GLP-1 backbone with an albumin-binding acylated lysine, so they share a receptor target and a general design. They differ in fatty-acid/linker chemistry (C16 spacer vs C18-OEG linker), molecular mass, and the backbone substitutions used to resist DPP-4 cleavage. They are not interchangeable as reference standards because their masses and impurity profiles differ.
- Do these GLP-1 standards need sequence verification, or is mass spec enough?
- For routine follow-up lots from a qualified supplier, RP-HPLC purity plus ESI-MS identity is the practical norm. Add LC-MS/MS sequence confirmation for first-time supplier qualification of either molecule and for any study where the acylation-site integrity is part of the endpoint, because an intact-mass check does not fully resolve a mis-positioned or incomplete acylation on a closely-related impurity.
- Are Liraglutide and Semaglutide reference standards finished drugs?
- No. Lyochem supplies both as bulk research reference standards for Research Use Only, characterized lot-by-lot at milligram scale, not labelled for human administration and not finished dosage forms. Some GLP-1 analogues exist as approved finished drugs under separate brand names, but the material supplied here is a research reagent; buyers are responsible for institutional biosafety review and verifying import eligibility in the destination market.